Wedbush Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wedbush Securities’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,979	Closed	-$247K	–	1053
2022 Q2	$247K	Sell	2,979 -386	-11%	-$30.7K	0.01%	828
2022 Q1	$259K	Buy	3,365 +563	+20%	+$47.1K	0.01%	866
2021 Q4	$248K	Buy	+2,802	New	+$231K	0.01%	963
2020 Q3	–	Sell	-1,738	Closed	-$214K	–	944
2020 Q2	$214K	Sell	1,738 -1,388	-44%	-$138K	0.02%	752
2020 Q1	$264K	Buy	3,126 +535	+21%	+$46.1K	0.03%	570
2019 Q4	$219K	Buy	+2,591	New	+$196K	0.02%	823
2018 Q4	–	Sell	-2,706	Closed	-$262K	–	840
2018 Q3	$262K	Sell	2,706 -74	-3%	-$7.39K	0.03%	646
2018 Q2	$262K	Buy	+2,780	New	+$243K	0.03%	607

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wedbush Securities's BMRN Position: Q3 2022 in Review

Wedbush Securities sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2022, closing a stake of 2,979 shares — an estimated $247K sold.

Wedbush Securities first reported a position in BMRN in Q2 2018 and held it in 8 quarters. The position peaked at $264K in Q1 2020. 551 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

Wedbush Securities reported no remaining BioMarin Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Wedbush Securities sold 2,979 BioMarin Pharmaceuticals shares in Q3 2022, an estimated $247K.
Wedbush Securities first reported a position in BioMarin Pharmaceuticals in Q2 2018 and held it in 8 quarters.
Wedbush Securities's BioMarin Pharmaceuticals position peaked at $264K in Q1 2020.
551 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on Wedbush Securities's 13F filing for Q3 2022, filed 18 Oct 2022.